Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly in the developed world. Current treatment options for AMD are available only to a limited number of patients with advanced "wet AMD". However, these treatments are initiated after vision loss has started and are designed to treat the lesion, i.e., sealing off leaking blood vessels, but do not address disease pathogenesis. Ideally, the most efficacious therapy for AMD should be started prior to vision loss and target the fundamental molecular defect, which requires defining disease mechanism.One current reseearch goal is to help define the molecular defects in retinal cells that are responsible for the pathology associated with AMD.INVESTIGATIONS OF RETINAL PROTEASOME The proteasome proteolytic complex plays a fundamental role in processes essential for cell viability, such as cell cycle regulation, control of signal transduction and gene expression, and the degradation of oxidized and misfolded proteins. A recent focus of our lab has been to define conditions that provoke the upregulation of immunoproteasome in the central nervous system. Data derived from this experimental approach provide some indication that immunoproteasome's function goes beyond its well-defined role in immune surveillance.